Mizuho Initiates Coverage on Audentes Therapeutics (NASDAQ:BOLD)

Mizuho started coverage on shares of Audentes Therapeutics (NASDAQ:BOLD) in a research note published on Monday, February 12th, MarketBeat.com reports. The firm issued a neutral rating and a $26.00 target price on the biotechnology company’s stock.

A number of other research firms also recently issued reports on BOLD. Raymond James Financial reiterated a hold rating on shares of Audentes Therapeutics in a research report on Thursday, January 4th. William Blair reiterated a buy rating on shares of Audentes Therapeutics in a research report on Friday, January 5th. BMO Capital Markets set a $44.00 price target on shares of Audentes Therapeutics and gave the company a buy rating in a research report on Friday, January 5th. Zacks Investment Research cut shares of Audentes Therapeutics from a hold rating to a sell rating in a research note on Monday, January 22nd. Finally, Wedbush raised their price objective on shares of Audentes Therapeutics to $56.00 and gave the stock an outperform rating in a research note on Thursday, January 4th. One analyst has rated the stock with a sell rating, three have given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $34.00.

Shares of Audentes Therapeutics (NASDAQ BOLD) traded down $0.78 during trading hours on Monday, reaching $33.51. 116,800 shares of the company were exchanged, compared to its average volume of 525,915. Audentes Therapeutics has a 1 year low of $13.90 and a 1 year high of $41.80.

In other news, VP Suyash Prasad sold 8,000 shares of the business’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $28.53, for a total transaction of $228,240.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Louis G. Lange sold 18,000 shares of the business’s stock in a transaction on Friday, December 22nd. The shares were sold at an average price of $30.88, for a total transaction of $555,840.00. The disclosure for this sale can be found here. 47.30% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Schwab Charles Investment Management Inc. lifted its holdings in shares of Audentes Therapeutics by 139.3% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 25,600 shares of the biotechnology company’s stock valued at $490,000 after acquiring an additional 14,900 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Audentes Therapeutics by 180.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 52,900 shares of the biotechnology company’s stock valued at $1,012,000 after acquiring an additional 34,057 shares in the last quarter. Teachers Advisors LLC lifted its holdings in shares of Audentes Therapeutics by 342.5% during the 2nd quarter. Teachers Advisors LLC now owns 26,926 shares of the biotechnology company’s stock valued at $515,000 after acquiring an additional 20,841 shares in the last quarter. TIAA CREF Investment Management LLC lifted its holdings in Audentes Therapeutics by 459.3% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 64,497 shares of the biotechnology company’s stock worth $1,234,000 after buying an additional 52,965 shares in the last quarter. Finally, Nationwide Fund Advisors lifted its holdings in Audentes Therapeutics by 288.9% in the 2nd quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock worth $164,000 after buying an additional 6,384 shares in the last quarter. 67.36% of the stock is owned by institutional investors.

WARNING: This piece was posted by Week Herald and is the property of of Week Herald. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://weekherald.com/2018/02/19/mizuho-begins-coverage-on-audentes-therapeutics-bold.html.

About Audentes Therapeutics

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply